BICX: AI 评分 52/100 — AI 分析 (4月 2026)

BioCorRx Inc. develops and provides treatment programs for substance abuse and related disorders in the United States. The company distributes and licenses the BioCorRx recovery program and UnCraveRx weight loss management program.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

BioCorRx Inc. focuses on developing and distributing treatment programs for substance abuse and weight management, featuring its BioCorRx recovery program and UnCraveRx. Operating within the medical care facilities sector, the company leverages medication-assisted treatments and virtual support to address addiction and weight-related disorders in the United States.

BICX是做什么的？

BioCorRx Inc., formerly known as Fresh Start Private Management, Inc. until its name change in January 2014, is dedicated to developing and providing treatment programs for substance abuse and related disorders in the United States. The company's core offering includes the BioCorRx recovery program, a non-addictive, medication-assisted treatment that combines a counseling program with its proprietary naltrexone implant. This program is distributed and licensed to healthcare providers, independent licensed clinics, and licensed healthcare professionals. In addition to substance abuse treatment, BioCorRx also offers the UnCraveRx weight loss management program. This medically assisted program aims to reduce food cravings through medication, coupled with on-demand virtual lifestyle support, fitness resources, and nutritional guidance. This dual approach addresses both addiction and weight management, reflecting a comprehensive approach to health and wellness. BioCorRx is also actively developing new products, including BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant specifically designed for the treatment of opioid addiction and alcoholism. These pipeline products indicate the company's commitment to expanding its treatment options and addressing critical needs in the addiction treatment landscape. Headquartered in Anaheim, California, BioCorRx operates primarily within the United States, focusing on providing innovative solutions for substance abuse and weight management.

BICX的投资论点是什么？

BioCorRx Inc. presents a speculative investment opportunity within the substance abuse and weight management sectors. The company's proprietary naltrexone implant technology and the UnCraveRx program offer potential revenue streams, though profitability remains a challenge, as reflected in the negative P/E ratio of -1.41 and a substantial negative profit margin of -510.3%. The development of BICX101 and BICX104 could serve as future catalysts, pending regulatory approvals and successful clinical trials. The company's small market capitalization of $0.01 billion and limited number of employees (3) suggest a high-risk, high-reward scenario, contingent on successful product commercialization and market penetration. Investors should carefully consider the company's financial position and the competitive landscape before investing.

BICX在哪个行业运营？

BioCorRx Inc. operates within the medical care facilities industry, addressing the growing needs for substance abuse and weight management solutions. The market for addiction treatment is expanding, driven by increasing awareness and the opioid crisis. The weight management market is also substantial, fueled by rising obesity rates and demand for effective solutions. BioCorRx competes with companies like BVAXF, FAMDF, GBCS, HLYK, and IONKF, which offer various treatment options and programs. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and effectively market its programs to healthcare providers and individuals.

Medical - Care Facilities

Healthcare

BICX有哪些增长机遇？

Expansion of the BioCorRx Recovery Program: The market for medication-assisted treatment (MAT) is growing, driven by the opioid crisis and increasing acceptance of MAT as an effective treatment modality. BioCorRx can expand its reach by partnering with more healthcare providers and clinics across the United States. The addressable market for MAT is estimated to be billions of dollars, offering significant growth potential for BioCorRx.
Development and Commercialization of BICX101 and BICX104: The successful development and approval of BICX101 (injectable naltrexone) and BICX104 (implantable naltrexone) represent significant growth opportunities. These products could provide more convenient and effective treatment options for opioid addiction and alcoholism. The market for long-acting injectable and implantable naltrexone products is substantial, with potential for significant revenue generation upon successful commercialization.
Growth of the UnCraveRx Weight Loss Management Program: The weight loss market is a multi-billion dollar industry, driven by increasing obesity rates and demand for effective weight management solutions. BioCorRx can expand its UnCraveRx program by enhancing its virtual support platform, adding new features, and targeting specific customer segments. The program's medically assisted approach and virtual support offer a differentiated value proposition.
Strategic Partnerships and Acquisitions: BioCorRx can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and market share. Collaborating with other healthcare providers, technology companies, or pharmaceutical companies could accelerate growth and enhance the company's competitive position. Potential acquisition targets could include companies with complementary technologies or treatment programs.
International Expansion: While currently focused on the United States, BioCorRx can explore opportunities for international expansion. The need for substance abuse and weight management solutions exists globally, and BioCorRx's programs could be adapted for use in other countries. International expansion would require careful planning and execution, but it could significantly expand the company's addressable market and revenue potential.

Market capitalization of $0.01 billion, indicating a micro-cap company with high growth potential but also significant risk.
P/E ratio of -1.41, reflecting current unprofitability but potential for future earnings growth.
Gross margin of 53.9%, suggesting a solid foundation for profitability if operational costs are managed effectively.
Negative profit margin of -510.3%, highlighting significant challenges in achieving profitability.
Beta of 0.30, indicating lower volatility compared to the overall market.

BICX提供哪些产品和服务？

Develops treatment programs for substance abuse and related disorders.
Provides medication-assisted treatment programs.
Distributes and licenses the BioCorRx recovery program, a non-addictive treatment.
Offers a counseling program coupled with a proprietary naltrexone implant.
Distributes the UnCraveRx weight loss management program.
Provides medically assisted weight management to reduce food cravings.
Offers on-demand virtual lifestyle support, fitness, and nutrition.
Develops BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant.

BICX如何赚钱？

Licensing and distribution of the BioCorRx recovery program to healthcare providers and clinics.
Direct sales of the UnCraveRx weight loss management program to individuals.
Potential future revenue from sales of BICX101 and BICX104 upon regulatory approval.
Partnerships with healthcare professionals for program implementation.

Healthcare providers and independent licensed clinics.
Licensed healthcare professionals.
Individuals seeking treatment for substance abuse.
Individuals seeking medically assisted weight management solutions.

Proprietary naltrexone implant technology.
Integrated counseling program with medication-assisted treatment.
Virtual support platform for weight management.
Development of new injectable and implantable naltrexone products.

什么因素可能推动BICX股价上涨？

Upcoming: Potential FDA approval of BICX101 (injectable naltrexone).
Upcoming: Potential FDA approval of BICX104 (implantable naltrexone).
Ongoing: Expansion of the BioCorRx recovery program to new healthcare providers.
Ongoing: Growth in sales of the UnCraveRx weight loss management program.
Ongoing: Strategic partnerships and acquisitions.

BICX的主要风险是什么？

Potential: Regulatory delays or rejection of BICX101 and BICX104.
Potential: Competition from established pharmaceutical companies.
Ongoing: Negative profitability and high operating expenses.
Ongoing: Reliance on a small number of employees.
Ongoing: Limited financial disclosure due to OTC listing.

BICX的核心优势是什么？

Proprietary naltrexone implant technology.
Integrated counseling and medication-assisted treatment approach.
Virtual support platform for weight management.
Development pipeline of new naltrexone products (BICX101, BICX104).

BICX的劣势是什么？

Small market capitalization and limited resources.
Negative profitability and high operating expenses.
Reliance on a small number of employees.
OTC market listing, which may limit investor access.

BICX有哪些机遇？

Expansion of the BioCorRx recovery program to more healthcare providers.
Commercialization of BICX101 and BICX104.
Growth of the UnCraveRx weight loss management program.
Strategic partnerships and acquisitions.

BICX面临哪些威胁？

Competition from established pharmaceutical companies and treatment centers.
Regulatory hurdles and potential delays in product approvals.
Changes in healthcare policies and reimbursement rates.
Potential for product liability claims.

BICX的竞争对手是谁？

Braxia Scientific Corp. — Focuses on innovative ketamine treatments for mental health disorders. — (BVAXF)
FSD Pharma Inc. — Develops cannabinoid-based pharmaceutical products. — (FAMDF)
GBCS Corp. — Unknown differentiation due to lack of available information. — (GBCS)
HLYK — Unknown differentiation due to lack of available information. — (HLYK)
iONCTURA INC. — Develops innovative cancer therapies. — (IONKF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Lourdes Felix
Headquarters: Anaheim, US
Employees: 3
Founded: 2010

AI Insight

AI analysis pending for BICX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does BioCorRx Inc. do?

BioCorRx Inc. develops and provides treatment programs for substance abuse and weight management. Its primary product is the BioCorRx recovery program, which combines counseling with a proprietary naltrexone implant to treat addiction. The company also offers the UnCraveRx weight loss management program, a medically assisted program with virtual support. Additionally, BioCorRx is developing BICX101 and BICX104, injectable and implantable naltrexone products, respectively, aimed at treating opioid addiction and alcoholism. BioCorRx distributes its programs to healthcare providers and licensed professionals.

What do analysts say about BICX stock?

There is currently no available analyst coverage or consensus on BioCorRx Inc. (BICX) due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are unavailable. Potential investors should conduct their own due diligence and consider the company's financial position, growth prospects, and risk factors before making any investment decisions. The lack of analyst coverage highlights the speculative nature of this investment.

What are the main risks for BICX?

BioCorRx Inc. faces several key risks, including its small market capitalization, negative profitability, and reliance on a limited number of employees. As an OTC-listed company, it has limited financial disclosure and liquidity, increasing the risk of price volatility and potential fraud. The company's success depends on the successful development and commercialization of BICX101 and BICX104, which are subject to regulatory approval and competition from established pharmaceutical companies. Changes in healthcare policies and reimbursement rates could also negatively impact the company's financial performance.